Antoine Piau, La Cité de la Santé, Bâtiment Ex-Biochimie, Hôpital La Grave, Place Lange, TSA 60033, 31059 Toulouse Cedex 9, France, E-mail address:
J Frailty Aging. 2021;10(2):132-138. doi: 10.14283/jfa.2020.51.
The WHO action plan on aging expects to change current clinical practices by promoting a more personalized model of medicine. To widely promote this initiative and achieve this goal, healthcare professionals need innovative monitoring tools. Use of conventional biomarkers (clinical, biological or imaging) provides a health status assessment at a given time once a capacity has declined. As a complement, continuous monitoring thanks to digital biomarkers makes it possible to remotely collect and analyze real life, ecologically valid, and continuous health related data. A seamless assessment of the patient's health status potentially enables early diagnosis of IC decline (e.g. sub-clinical or transient events not detectable by episodic evaluations) and investigation of its probable causes. This narrative review aims to develop the concept of digital biomarkers and its implementation in IC monitoring.
世卫组织老龄化行动计划预计将通过推广更个性化的医学模式来改变当前的临床实践。为了广泛推广这一倡议并实现这一目标，医疗保健专业人员需要创新的监测工具。使用传统的生物标志物（临床、生物或影像学）在能力下降后提供一次给定时间的健康状况评估。作为补充，借助数字生物标志物进行连续监测，可以远程收集和分析现实生活中生态有效的连续健康相关数据。对患者健康状况的无缝评估有可能实现对认知障碍下降的早期诊断（例如，间歇性评估无法检测到的亚临床或短暂事件），并调查其可能的原因。本叙述性综述旨在阐述数字生物标志物的概念及其在认知障碍监测中的应用。
